Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Organization

Univ. of Oxford, Oxford, United Kingdom

1 abstract

Abstract
12-WEEK RESULTS OF A PHASE 2B DOSE-RANGING STUDY OF LY3009104 (INCB028050), AN ORAL JAK1/JAK2 INHIBITOR, IN COMBINATION WITH TRADITIONAL DMARDS IN PATIENTS WITH RHEUMATOID ARTHRITIS
Org: Mount Sinai Hospital, Toronto, Canada, Univ. of Oxford, Oxford, United Kingdom, Stanford Univ., Palo Alto, Eli Lilly & Co, Indianapolis, Incyte Corp., Wilmington, United States,